protein kinase, cGMP-dependent, type I | |
---|---|
Crystallographic structure of the leucine zipper domain of human cGMP dependent protein kinase I beta.[1] | |
Identifiers | |
Symbol | PRKG1 |
Alt. symbols | PRKGR1B, PRKG1B |
Entrez | 5592 |
HUGO | 9414 |
OMIM | 176894 |
RefSeq | NM_006258 |
UniProt | P14619 |
Other data | |
Locus | Chr. 10 q11.2 |
protein kinase, cGMP-dependent, type II | |
---|---|
Identifiers | |
Symbol | PRKG2 |
Entrez | 5593 |
HUGO | 9416 |
OMIM | 601591 |
RefSeq | NM_006259 |
UniProt | Q13237 |
Other data | |
Locus | Chr. 4 q13.1-21.1 |
cGMP-dependent protein kinase or Protein Kinase G (PKG) is a serine/threonine-specific protein kinase that is activated by cGMP. It phosphorylates a number of biologically important targets and is implicated in the regulation of smooth muscle relaxation, platelet function, sperm metabolism, cell division, and nucleic acid synthesis.
Contents |
PKG are serine/threonine kinases that are present in a variety of eukaryotes ranging from the unicellular organism Paramecium to humans. Two PKG genes, coding for PKG type I (PKG-I) and type II (PKG-II), have been identified in mammals. The N-terminus of PKG-I is encoded by two alternatively spliced exons that specify for the PKG-Iα and PKG-Iβ isoforms. PKG-Iβ is activated at ~10-fold higher cGMP concentrations than PKG-Iα. The PKG-I and PKG-II are homodimers of two identical subunits (~75 kDa and ~85 kDa, respectively) and share common structural features.
Each subunit is composed of three functional domains:
Binding of cGMP to the regulatory domain induces a conformational change that releases the inhibition of the catalytic core by the N-terminus and allows the phosphorylation of substrate proteins. Whereas PKG-I is predominantly localized in the cytoplasm, PKG-II is anchored to the plasma membrane by N-terminal myristoylation.
In general, PKG-I and PKG-II are expressed in different cell types.
Specifically, in smooth muscle tissue, PKG phosphorylates and inhibits the Myosin light chain kinase which normally phosphorylates the myosin light chains, thus initiating smooth muscle relaxation.
Cancerous colon cells stop producing PKG, which apparently limits beta-catenin thus allowing the VEGF enzyme to solicit angiogenesis.[2]
|